RxDoctor Payments Data

George Knefely, MD

Internal Medicine · Pensacola, FLNPI 1659366409

Payments from drug & device makers

$1,064in general payments, 2019–2025

Across 63 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$146
  • Sanofi-aventis U.S. LLC$131
  • Boehringer Ingelheim$115
  • Pfizer$112
  • Novartis$104
  • Amgen$102
  • plus $354 from 5 others

What the payments were for

  • Food & beverage$1,064100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,064 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$49,690
Medicare patients
156
Services billed
484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban101$113,785
JardianceEmpagliflozin65$86,221
FarxigaDapagliflozin Propanediol55$67,784
MounjaroTirzepatide53$53,918
XareltoRivaroxaban41$51,244
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$46,911
OzempicSemaglutide33$46,589
MyrbetriqMirabegron19$24,227
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$21,311
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$18,097
Rosuvastatin Calcium388$6,447
Losartan Potassium442$5,566
Clonidine16$5,562
Atorvastatin Calcium394$4,996
Metoprolol Succinate208$4,254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$112$113,785101 claims
Boehringer IngelheimJardiance$115$86,22165 claims
GSKTrelegy Ellipta, Anoro Ellipta$60$68,22254 claims
AstraZenecaFarxiga$146$67,78455 claims
Lilly USA, LLCMounjaro$73$53,91853 claims
Johnson & JohnsonXarelto$95$51,24441 claims
Novo NordiskOzempic$86$46,58933 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →